Uncover key drivers, emerging technologies, and competitive movements shaping the ischemic heart disease (ihd) drugs market from 2025–2034 with trusted insights from The Business Research Company
What Is The Projected Valuation Of The Ischemic Heart Disease (IHD) Drugs Market In The Period 2029-2034?
The ischemic heart disease (IHD) drugs market size has demonstrated consistent growth in recent years. It is projected to increase from $6.36 billion in 2024 to $6.65 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.5%. The expansion witnessed in prior periods can be attributed to the rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, and insurance coverage and reimbursement policies.
The ischemic heart disease (IHD) drugs market size is anticipated to experience consistent expansion in the coming years, projected to reach “$7.7 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. This expansion during the forecast period is driven by factors such as aging population trends, personalized medicine approaches, a heightened emphasis on cardiovascular prevention, global health policies and initiatives, and international research collaborations. Key trends expected in the forecast period involve a shift towards precision medicine strategies, a focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, the integration of anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.
Access A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
What Strategic Drivers Are Accelerating The Ischemic Heart Disease (IHD) Drugs Market Expansion?
An increasing incidence of obesity and diabetes is anticipated to fuel the expansion of the ischemic heart disease (IHD) drugs market in the future. Diabetes is a chronic metabolic disorder resulting in elevated blood glucose, while obesity describes a health condition marked by excessive body fat accumulation detrimental to well-being. Medications for ischemic heart disease are commonly administered to patients with obesity and diabetes to control cardiovascular risk factors, including hypertension and dyslipidemia, thereby lessening the chance of developing ischemic heart disease. For example, insights from the World Obesity Federation, a UK-based organization leading worldwide efforts to address obesity, indicated in 2022 that by 2030, one billion individuals globally, comprising 1 in 5 women and 1 in 7 men, are projected to be living with obesity. Furthermore, the National Health Service, a UK-based government entity, reported in June 2024 that during 2023, the NHS identified more than 549,000 new individuals in England facing a risk of type 2 diabetes, elevating the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This figure signifies a considerable increase from 3,065,825 recorded in 2022, showing a growth of nearly 20%. Consequently, the increasing occurrence of obesity and diabetes acts as a key driver for the expansion of the ischemic heart disease (IHD) drugs market.
What Is The Detailed Segment Distribution Of The Ischemic Heart Disease (IHD) Drugs Market?
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
How Are Global Trends Impacting The Development Of The Ischemic Heart Disease (IHD) Drugs Market?
Major companies in the ischemic heart disease (IHD) drugs market are increasingly focusing on developing innovative myosin inhibitors to gain a competitive edge. A cardiac myosin inhibitor is a medication that lessens myosin activity in the heart muscle, thereby reducing contraction force. This is beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs heart function. For example, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, introduced Camzyos (mavacamten). This is the first cardiac myosin inhibitor approved for treating adults with symptomatic New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve their functional capacity and symptoms. The drug functions as an allosteric and reversible inhibitor selective for cardiac myosin, leading to reduced hypercontractility, decreased left ventricular hypertrophy, and improved cardiac filling pressures. This action aids in decreasing dynamic left ventricular outflow tract (LVOT) obstruction.
Who Are The Major Stakeholders Operating In The Ischemic Heart Disease (IHD) Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Download The Full Report Here:
Which Region Is Projected To Achieve The Fastest Growth In The Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get A Report Customized For You Here:
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp
Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company
Antiparasitic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Global Market Report 2025
Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model